Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

mab may represent a valuable new approach to treating cancer," said Dr. Raghunadharao Digumarti, professor of medical oncology at the Nizams Institute of Medical Sciences and a Phase II bavituximab cancer trial investigator who presented the data at ASCO on behalf of the study team. "We are pleased with the response rates and progression free survival data seen in the initial group of breast cancer patients and look forward to reporting additional results from the entire Phase II breast cancer study later this year."

The primary objective of this multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. In the trial's two-stage design, 15 patients with advanced breast cancer were enrolled in the first cohort. The 71% objective tumor response rate seen in the 14 evaluable patients in the first cohort compares favorably with historical response rates for docetaxel as solo therapy in advanced breast cancer patients and it exceeded the pre-specified primary endpoint needed to expand the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall. With patient enrollment complete, dosing and follow-up are continuing. The safety profile of bavituximab plus docetaxel in the study has been acceptable, with minor infusion reactions, epistaxis and nasal dryness among the most common reported bavituximab-related side effects. These did not require dose modification or treatment discontinuation.

Separately, Peregrine reported that researchers will present data at ASCO today from a Phase I study assessing the safety and pharmacokinetic (PK) properties of bavituximab as monotherapy in patients with advanced refractory cancers. This multi-center open label safety study is currently enrolling patients in the final cohort according to the initial study design. The study authors report on their experience with the first 25 patients in the st
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Sodium ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... China Acetic Acid Industry" is a professional and ... and Global Acetic Acid Market. The report ...
(Date:9/18/2014)... Washington, D.C. (PRWEB) September 18, 2014 ... Dick Durbin and Sen. Jim Risch for National Lab ... research projects from across the national laboratory system. Durbin ... Caucus, which aims to increase awareness of the reach ... breakthrough technologies and discoveries to address some of our ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 ... en 1974, a été depuis 40 ... les évaluations cliniques traditionnelles par des évaluations ... et sur les impacts économiques des traitements. ... A cours d,une récente ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 21974 - 2014 - Mapi fête ses 40 ans 2
... July 28, 2011 As the fight over deficit reform ... Association (NEBA) is urging lawmakers from across the region to ... economy and ensure it doesn,t become a victim of short-sighted ... options for treatment and medications available to seniors, but would ...
... (NASDAQ: ITMN ) today announced that it will ... 4, 2011. A live conference call and webcast will be ... day to discuss business highlights and financial results for the ... To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 ...
... INDIANAPOLIS, and WALTHAM, Mass., July 28, 2011 ... Eli Lilly and Company (NYSE: LLY ) and ... the companies have submitted their reply to a complete response ... Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), ...
Cached Biology Technology:Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy 2InterMune to Release Second Quarter Financial Results on August 4 2BYDUREON™ Reply Submitted to FDA 2BYDUREON™ Reply Submitted to FDA 3BYDUREON™ Reply Submitted to FDA 4BYDUREON™ Reply Submitted to FDA 5BYDUREON™ Reply Submitted to FDA 6BYDUREON™ Reply Submitted to FDA 7
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Greenhouse gas research enters a new era 2How stress tears us apart 2
... infected with human immunodeficiency virus (HIV), highly active ... of Kaposi sarcoma and non-Hodgkin lymphoma, according to ... of the Journal of the National Cancer Institute. ... (AIDS) have reported increased risks of several cancers, ...
... phase 3 HIV vaccine efficacy trial are reported in the ... available online. Although the vaccine was ineffective in preventing HIV ... HIV and offers the scientific community a foundation on which ... the United States and the Netherlands and completed in 2003, ...
... University of Pennsylvania School of Medicine have identified a ... Virus (EBV) protein known to be expressed in a ... mechanism by which EBV transforms human B cells from ... to development of B-cell lymphomas. , Erle S. Robertson, ...
Cached Biology News:Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2HIV vaccine trial breaks ground for future research 2Epstein-Barr virus protein crucial to its role in blood cancers 2
... applications for the use of small interfering ... via the RNA interference (RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... or enzymatically, and then transfected into the ...
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
a1-Antitrypsin (human, alpha-1 AT)...
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
Biology Products: